Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NAGE Niagen Bioscience Inc.
- Stocks
- Healthcare
- NASDAQ: NAGE
Price (delayed)
$11.79
Market cap
$928.69M
P/E Ratio
65.5
Dividend/share
N/A
EPS
$0.18
Enterprise value
$876.6M
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide
Highlights
The equity has surged by 91% year-on-year and by 20% since the previous quarter
NAGE's quick ratio has surged by 71% year-on-year and by 3.1% since the previous quarter
Niagen Bioscience's debt has increased by 33% from the previous quarter and by 9% YoY
Key stats
What are the main financial stats of NAGE
Market
Valuations
Earnings
Shares outstanding
78.77M
Market cap
$928.69M
Enterprise value
$876.6M
Price to earnings (P/E)
65.5
Price to book (P/B)
16.56
Price to sales (P/S)
8.5
EV/EBIT
60.13
EV/EBITDA
54.65
EV/Sales
8.12
Revenue
$107.93M
Gross profit
$67.46M
Operating income
$13.23M
Net income
$14.11M
EBIT
$14.58M
EBITDA
$16.04M
Free cash flow
$19.56M
Per share
Balance sheet
Liquidity
EPS
$0.18
EPS diluted
$0.17
Free cash flow per share
$0.25
Book value per share
$0.71
Revenue per share
$1.39
TBVPS
$1.04
Total assets
$81.34M
Total liabilities
$25.99M
Debt
$3.52M
Equity
$55.35M
Working capital
$55.38M
Debt to equity
0.06
Current ratio
3.66
Quick ratio
3.01
Net debt/EBITDA
-3.25
Margins
Efficiency
Dividend
EBITDA margin
14.9%
Gross margin
62.5%
Net margin
13.1%
Operating margin
12.3%
Return on assets
21.7%
Return on equity
33.9%
Return on invested capital
162.2%
Return on capital employed
24.1%
Return on sales
13.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NAGE stock price
How has the Niagen Bioscience stock price performed over time
Intraday
-2.72%
1 week
-7.24%
1 month
-12.8%
1 year
348.29%
YTD
122.24%
QTD
-18.18%
Financial performance
How have Niagen Bioscience's revenue and profit performed over time
Revenue
$107.93M
Gross profit
$67.46M
Operating income
$13.23M
Net income
$14.11M
Gross margin
62.5%
Net margin
13.1%
Niagen Bioscience's operating income has surged by 71% QoQ
The company's net income has surged by 65% QoQ
NAGE's operating margin has surged by 58% since the previous quarter
Niagen Bioscience's net margin has soared by 52% from the previous quarter
Price vs fundamentals
How does NAGE's price correlate with its fundamentals
Growth
What is Niagen Bioscience's growth rate over time
Valuation
What is Niagen Bioscience stock price valuation
P/E
65.5
P/B
16.56
P/S
8.5
EV/EBIT
60.13
EV/EBITDA
54.65
EV/Sales
8.12
The company's EPS has surged by 64% QoQ
NAGE's price to book (P/B) is 105% higher than its last 4 quarters average of 8.3 and 103% higher than its 5-year quarterly average of 8.4
The equity has surged by 91% year-on-year and by 20% since the previous quarter
NAGE's price to sales (P/S) is 143% higher than its last 4 quarters average of 3.6 and 136% higher than its 5-year quarterly average of 3.7
The revenue has grown by 30% YoY and by 8% from the previous quarter
Efficiency
How efficient is Niagen Bioscience business performance
NAGE's return on invested capital has surged by 73% since the previous quarter
The company's return on sales has surged by 52% QoQ
Niagen Bioscience's return on assets has increased by 48% QoQ
The company's return on equity rose by 39% QoQ
Dividends
What is NAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NAGE.
Financial health
How did Niagen Bioscience financials performed over time
NAGE's quick ratio has surged by 71% year-on-year and by 3.1% since the previous quarter
The total assets has soared by 50% YoY and by 19% from the previous quarter
Niagen Bioscience's debt is 94% less than its equity
The equity has surged by 91% year-on-year and by 20% since the previous quarter
NAGE's debt to equity is down by 45% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.